Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting
Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience
Francesca De Nard¹, Vittorio Grosso², Monica Todoerti³, Carlomaurizio Montecucco⁴ and Roberto Caporali⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, ³Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁵Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…
Abstract Number: 80 • 2014 ACR/ARHP Annual Meeting
Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry
Michael Kruse Meyer¹, Marlene Andersen², Grethe N. Andersen¹ and Allan Stensballe³, ¹Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, ²Department of Rheumatology, Aalborg University, Hjørring, Denmark, ³Health Science and Technology, Aalborg University, Aalborg, Denmark
Background/Purpose: In this study we are analyzing leukocyte subtype responses from patients with rheumatoid arthritis (RA) to IL6 inhibition. A large contribution to RA immunopathogenesis…
Abstract Number: 448 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards: A Registry-Based Comparison Study
Cem Gabay¹, Myriam Riek², Merete Lund Hetland³, Ulrik Tarp⁴, K. Pavelka⁵, Matija Tomsic⁶, Helena Canhao⁷, Katerina Chatzidionysiou⁸, R.F. van Vollenhoven⁹, Galina Lukina¹⁰, E. Nasonov¹¹, Dan C. Nordström¹², Elisabeth Lie¹³, Ioan Ancuta¹⁴, Estibaliz Loza Santamaria¹⁵, Piet Van Riel¹⁶ and Tore K. Kvien¹³, ¹Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²SCQM Registry, Zurich, Switzerland, ³DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁶Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, ⁷Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ⁸Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁹Karolinska Institute, Stockholm, Sweden, ¹⁰ARBITER, Institute of Rheumatology, Moscow, Russia, ¹¹Institute of Rheumatology, Moscow, Russia, ¹²ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, ¹³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁴“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ¹⁵Instituto de salud Musculoesqueletica, Madrid, Spain, ¹⁶Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Tocilizumab (TCZ) is efficacious in monotherapy and in combination with methotrexate (MTX) or other DMARDs. However, longitudinal data from large registry populations are missing.…
Abstract Number: 451 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data 3 In Patients With Rheumatoid Arthritis Receiving Tocilizumab
Yu F. Asanuma¹, Takashi Maruyama², Maiko Yanagisawa², Kazuhiro Yokota³, Yoshihiro Yoshida², Hiroshi Kajiyama¹, Kojiro Sato¹, Yuji Akiyama¹ and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Interleukin-6 (IL-6) has been demonstrated to play a pathological role in rheumatoid arthritis (RA). IL-6 strongly induces production of C-reactive protein (CRP) and fibrinogen…
Abstract Number: 359 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At 3.0 Tesla
Hitomi Kobayashi^1,2, Isamu Yokoe³, Hiroshi Sato², Yasuyuki Kobayashi⁴, Kihei Yoneyama⁵, Masaharu Hirano⁶ and Masami Takei⁷, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ³Nihon University School of Medicine, Tokyo, Japan, ⁴Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁵Cardiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁶Cardiology, Tokyo Medical Colleage, Tokyo, Japan, ⁷Division of Hematology and Rheumatology, NIhon University School of Medicine, Tokyo, Japan
Background/Purpose: Left ventricular (LV) dysfunction in rheumatoid arthritis (RA) may result, at least in part, from inflammation that may be regional and global. Therefore, therapies…
Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting
Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed⁴, Jeffrey D. Greenberg⁵, Ashwini Shewade², Daniel H. Solomon⁶, Joel M. Kremer⁷ and Tanya Sommers⁴, ¹Columbia University, New York, NY, ²Genentech Inc., South San Francisco, CA, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴CORRONA, Inc., Southborough, MA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…
Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting
Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient
Chisa Okura¹, Yukio Yonemoto², Koichi Okamura¹, Tetsuya Kaneko³, Tsutomu Kobayashi¹ and Kenji Takagishi¹, ¹Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, ³Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan
Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…
Abstract Number: 2389 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Survives Introducing The Hemadialysis Longer Than Oral Medicine In AA Amyloidosis Patients With Rheumatoid Arthritis Of Renal Insufficiency
Osamu Saiki¹, Hiroshi Uda¹, Ayumi Matsumoto², Aya Mizumoto³, Tamaki Harada³ and Toshirou Takama³, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Higashiosaka City General Hospital, Higashiosaka, Japan, ³Nephrology, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: In AA amyloidosis patients with RA taking oral medicines such as methotrexate and prednisolone, it is generally accepted that the renal function deteriorates gradually…
Abstract Number: 2390 • 2013 ACR/ARHP Annual Meeting
Low Dose Of Tocilizumab Can Be Effective In RA Patients Who Achieve Remission.
Cecilia Prieto- Candau¹, Virginia Moreira- Navarrete², Carmen Vargas-Lebrón², Juan M Prieto-Martinez², Dolores Ruiz-Montesinos², Javier Toyos-Saenz de Miera² and Federico Navarro-Sarabia³, ¹Rheumatology, Hospital Virgen Macarena, SEVILLE, Spain, ²Rheumatology, Hospital Virgen Macarena, Seville, Spain, ³Rheumatology, Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain
Background/Purpose: Tocilizumab (TCZ), an anti-IL-6-receptor antibody, is used for the treatment of moderate to severe rheumatoid arthritis (RA) in adults with inadequate response or intolerance…
Abstract Number: 2368 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Efficiently Halts Radiographic Progression In Patients With Rheumatoid Arthritis and Swollen Joint Counts Within a Year Predict Long-Term Radiographic Outcomes: Three Year Results From Michinoku Tocilizumab Study Group
Ryu Watanabe¹, Hiroshi Okuno², Tomonori Ishii¹, Yasuhiko Hirabayashi³ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ²Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, ³Rheumatology, Hikarigaoka Spellman Hospital, Sendai, Japan
Background/Purpose: One of the important therapeutic goals in patients with rheumatoid arthritis (RA) is to halt radiographic progression. Tocilizumab (TCZ), an IL-6 receptor antibody, has…
Abstract Number: 2343 • 2013 ACR/ARHP Annual Meeting
Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 24 Weeks Of a Tocilizumab Therapy In 22 Patients With Rheumatoid Arthritis
Martin Soubrier¹, Thomas Frayssac², Bruno Pereira³, Marion Couderc Sr.⁴, Coline Daron², Jean Jacques Dubost⁵, Sandrine Malochet-Guinamand⁴, Anne Tournadre⁴ and Sylvain Mathieu⁴, ¹Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ²CHU CLERMONT-FERRAND, Clermont-ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose: Increased incidence of cardiovascular diseases and sub-clinical atherosclerosis have been observed in rheumatoid arthritis (RA). Inflammation and traditional risk factors could be involved in…
Abstract Number: 2327 • 2013 ACR/ARHP Annual Meeting
Dose Reduction Of Tocilizumab In Rheumatoid Arthritis Patients With Low Disease Activity Is Feasible
Noortje van Herwaarden¹, Susan Herfkens-Hol¹, Aatke van der Maas¹, Bart J.F. van Den Bemt², Ronald F. van Vollenhoven³, Johannes W.J. Bijlsma⁴ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ³Karolinska Institute, Stockholm, Sweden, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Tocilizumab, at a registered dose of 8mg/kg, has proven to be effective in the treatment of rheumatoid arthritis. Clinical trial data show that a…
Abstract Number: 2263 • 2013 ACR/ARHP Annual Meeting
ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis
Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of tocilizumab (TCZ) for…
Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Toshihisa Kojima¹, Nobunori Takahashi², Koji Funahashi³, Shuji Asai¹, Masahiro Hanabayashi¹, Shinya Hirabara⁴, Nobuyuki Asai⁵ and Naoki Ishiguro², ¹Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁵Nagoya Univeristy Hospital, Nagoya, Japan
Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…
Abstract Number: 1437 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study
Thomas W.J. Huizinga¹, Philip G. Conaghan², Emilio Martin-Mola³, Georg Schett⁴, Howard Amital⁵, Ricardo M. Xavier⁶, Orrin Troum⁷, Maher Aassi⁸, Corrado Bernasconi⁹ and Maxime Dougados¹⁰, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B',, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, ⁶Rheumatology Division, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁷University of Southern California School of Medicine, Santa Monica, CA, ⁸F. Hoffmann-La Roche, Basel, Switzerland, ⁹Consultant, Basel, Switzerland, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: 24- and 52- week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO])…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].